Current Report Filing (8-k)
03 Mai 2023 - 10:08PM
Edgar (US Regulatory)
false00009498580000949858dei:OtherAddressMember2023-04-282023-04-2800009498582023-04-282023-04-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 28, 2023
ACHIEVE LIFE SCIENCES, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
Delaware
|
|
033-80623
|
|
95-4343413
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
22722 29th Drive SE,
Suite 100
Bothell,
WA
|
|
98021
|
|
1040 West Georgia,
Suite 1030
Vancouver,
BC,
Canada
|
|
V6E 4H1
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s Telephone Number, Including Area Code:
(604)
210-2217
1040 West Georgia Street, Suite 1030, Vancouver, British Columbia,
Canada V6E 4H1
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
|
Title of each class
|
Trading Symbol
|
Name of exchange on which registered
|
|
Common Stock, par value $0.001 per share
|
ACHV
|
The
NASDAQ Capital
Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act.
☐
Item 7.01 Regulation FD Disclosure.
On April 28, 2023, Achieve Life Sciences, Inc. (the “Company”)
updated the address of its principal executive offices. Effective
April 28, 2023, the Company has principal executive offices at each
of (i) 1040 West Georgia, Suite 1030, Vancouver, B.C., Canada, V6E
4H1 and (ii) 22722 29th Drive SE, Suite 100, Bothell, WA
98021.
The information in this Item 7.01 to this Current Report on Form
8-K, shall not be deemed to be “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section or
Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended
(the “Securities Act”). The information contained in this Item 7.01
shall not be incorporated by reference into any other filing under
the Exchange Act or under the Securities Act, except as shall be
expressly set forth by specific reference in such
filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
|
|
|
ACHIEVE LIFE SCIENCES, INC.
|
|
Date: May 3, 2023
|
/s/ John Bencich
|
|
|
John Bencich
Chief Executive Officer (Principal Executive and Financial
Officer)
|
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
Von Aug 2023 bis Sep 2023
Achieve Life Sciences (NASDAQ:ACHV)
Historical Stock Chart
Von Sep 2022 bis Sep 2023
